Behavioral Phenotypes of Disc1 Missense Mutations in Mice

Neuron

Volumn 54, Issue 3, 2007, Pages 387-402

  Clapcote, Steven J ^a   Lipina, Tatiana V ^a   Millar, J Kirsty ^b   Mackie, Shaun ^b   Christie, Sheila ^b   Ogawa, Fumiaki ^b   Lerch, Jason P ^c   Trimble, Keith ^c   Uchiyama, Masashi ^d   Sakuraba, Yoshiyuki ^d   Kaneda, Hideki ^d   Shiroishi, Toshihiko ^d   Houslay, Miles D ^e   Henkelman, R Mark ^c,f   Sled, John G ^c,f   Gondo, Yoichi ^d   Porteous, David J ^b   Roder, John C ^a,f  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

HUMDISEASE; MOLNEURO; SYSNEURO

Indexed keywords

AMFEBUTAMONE; CLOZAPINE; ETHYLNITROSOUREA; HALOPERIDOL; MUTANT PROTEIN; PROTEIN DERIVATIVE; PROTEIN DISC1; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; EXON; GENE MUTATION; LATENT INHIBITION; MENTAL DISEASE; MISSENSE MUTATION; MOUSE; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ALANINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DNA MUTATIONAL ANALYSIS; FEMALE; GLUTAMINE; HUMANS; LEUCINE; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUTATION, MISSENSE; NERVE TISSUE PROTEINS; NEURAL INHIBITION; PHENOTYPE; PROTEIN BINDING; REFLEX, ACOUSTIC; SUBCELLULAR FRACTIONS; THREONINE;

EID: 34247619460     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2007.04.015     Document Type: Article

References (86)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (1994), American Psychiatric Association, Washington, DC
2. Arguello P.A., and Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 52 (2006) 179-196
3. Aultman J.M., and Moghaddam B. Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berl.) 153 (2001) 353-364
4. Austin C.P., Ma L., Ky B., Morris J.A., and Shughrue P.J. DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. Neuroreport 14 (2003) 951-954
5. Austin C.P., Ky B., Ma L., Morris J.A., and Shughrue P.J. Expression of Disrupted-In-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 124 (2004) 3-10
6. Avgustinovich D.F., Lipina T.V., Bondar N.P., Alekseyenko O.V., and Kudryavtseva N.N. Features of the genetically defined anxiety in mice. Behav. Genet. 30 (2000) 101-109
7. Baillie G.S., MacKenzie S.J., McPhee I., and Houslay M.D. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 131 (2000) 811-819
8. Blackwood D.H., Fordyce A., Walker M.T., St Clair D.M., Porteous D.J., and Muir W.J. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am. J. Hum. Genet. 69 (2001) 428-433
9. Braff D.L., Grillon C., and Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49 (1992) 206-215
10. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl.) 156 (2001) 234-258
11. Cadenhead K.S., Geyer M.A., and Braff D.L. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. Am. J. Psychiatry 150 (1993) 1862-1867
12. Callicott J.H., Straub R.E., Pezawas L., Egan M.F., Mattay V.S., Hariri A.R., Verchinski B.A., Meyer-Lindenberg A., Balkissoon R., Kolachana B., et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. USA 102 (2005) 8627-8632
13. Camargo L.M., Collura V., Rain J.C., Mizuguchi K., Hermjakob H., Kerrien S., Bonnert P., Whiting P.J., and Brandon N.J. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry 12 (2007) 74-86
14. Cannon T.D., Hennah W., van Erp T.G.M., Thompson P.M., Lonnqvist J., Huttunen M., Gasperoni T., Tuulio-Henriksson A., Pirkola T., Toga A.W., et al. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch. Gen. Psychiatry 62 (2005) 1205-1213
15. Chen X.J., Kovacevic N., Lobaugh N.J., Sled J.G., Henkelman R.M., and Henderson J.T. Neuroanatomical differences between mouse strains as shown by high-resolution 3D MRI. Neuroimage 29 (2006) 99-105
16. Clapcote S.J., and Roder J.C. Deletion polymorphism of Disc1 is common to all 129 mouse substrains: implications for gene targeting studies of brain function. Genetics 173 (2006) 2407-2410
17. Clapcote S.J., Lazar N.L., Bechard A.R., and Roder J.C. Effects of the rd1 mutation and host strain on hippocampal learning in mice. Behav. Genet. 35 (2005) 591-601
18. Coghill E.L., Hugill A., Parkinson N., Davison C., Glenister P., Clements S., Hunter J., Cox R.D., and Brown S.D. A gene-driven approach to the identification of ENU mutants in the mouse. Nat. Genet. 30 (2002) 255-256
19. Craddock N., and Owen M.J. The beginning of the end for the Kraepelinian dichotomy. Br. J. Psychiatry 186 (2005) 364-366
20. Cryan J.F., and Holmes A. The ascent of mouse: advances in modeling human depression and anxiety. Nat. Rev. Drug Discov. 4 (2005) 775-790
21. David D.J., Renard C.E., Jolliet P., Hascoët M., and Bourin M. Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology (Berl.) 166 (2003) 373-382
22. Davis R.L., and Kiger J.A. Dunce mutants of Drosophila melanogaster: mutants defective in the cyclic AMP phosphodiesterase enzyme system. J. Cell Biol. 90 (1981) 101-107
23. Di Benedetto G., Terrin A., Prinz A., Herberg F., Cheung Y.-F., Elvassore N., Houslay M.D., and Zaccolo M. Multiple contiguous domains with different [cAMP] result from compartmentalised phosphodiesterases in HEK293 cells. J. Cell Biol. 175 (2006) 441-451
24. Egashira N., Tanoue A., Higashihara F., Fuchigami H., Sano K., Mishima K., Fukue Y., Nagai H., Takano Y., Tsujimoto G., et al. Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs. Neuropsychopharmacology 30 (2005) 1996-2005
25. Geyer M.A., and Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1071-1079
26. Gottesman I.I., and Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160 (2003) 636-645
27. Grillon C., Ameli R., Charney D.S., Krystal J., and Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry 32 (1992) 939-943
28. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
29. Hashimoto R., Numakawa T., Ohnishi T., Kumamaru E., Yagasaki Y., Ishimoto T., Mori T., Nemoto K., Adachi N., Izumi A., et al. Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology, and ERK signaling. Hum. Mol. Genet. 15 (2006) 3024-3033
30. Hasler G., Drevets W.C., Gould T.D., Gottesman I.I., and Manji H.K. Toward constructing an endophenotype strategy for bipolar disorders. Biol. Psychiatry 60 (2006) 93-105
31. Hennah W., Tuulio-Henriksson A., Paunio T., Ekelund J., Varilo T., Partonen T., Cannon T.D., Lonnqvist J., and Peltonen L. A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol. Psychiatry 10 (2005) 1097-1103
32. Hennah W., Thomson P., Peltonen L., and Porteous D. Beyond schizophrenia: the role of DISC1 in major mental illness. Schizophr. Bull. 32 (2006) 409-416
33. Hodgkinson C.A., Goldman D., Jaeger J., Persaud S., Kane J.M., Lipsky R.H., and Malhotra A.K. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am. J. Hum. Genet. 75 (2004) 862-872
34. Houslay M.D., Schafer P., and Zhang K. Phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10 (2005) 1503-1519
35. Huston E., Lumb S., Russell A., Catterall C., Ross A.H., Steele M.R., Bolger G.B., Perry M.J., Owens R.J., and Houslay M.D. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cyclic AMP specific phosphodiesterase, HSPDE4B3. Biochem. J. 328 (1997) 549-558
36. Insel T.R., and Scolnick E.M. Cure therapeutics and strategic interventions: raising the bar for mental health research. Mol. Psychiatry 11 (2006) 11-17
37. Ishizuka K., Paek M., Kamiya A., and Sawa A. A review of disrupted-in-schizophrenia-1 (disc1): neurodevelopment, cognition, and mental conditions. Biol. Psychiatry 59 (2006) 1189-1197
38. Ishizuka K., Chen J., Taya S., Li W., Millar J.K., Xu Y., Clapcote S.J., Hookway C., Morita M., Kamiya A., et al. Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice. Mol. Psychiatry (2007) in press
39. Justice M.J., Noveroske J.K., Weber J.S., Zheng B., and Bradley A. Mouse ENU mutagenesis. Hum. Mol. Genet. 8 (1999) 1955-1963
40. Kamiya A., Kubo K., Tomoda T., Takaki M., Youn R., Ozeki Y., Sawamura N., Park U., Kudo C., Okawa M., et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat. Cell Biol. 7 (2005) 1167-1178
41. Koike H., Arguello P.A., Kvajo M., Karayiorgou M., and Gogos J.A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl. Acad. Sci. USA 103 (2006) 3693-3697
42. Konarski J.Z., McIntyre R.S., Grupp L.A., and Kennedy S.H. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?. J. Psychiatry Neurosci. 30 (2005) 178-186
43. Kovacevic N., Henderson J.T., Chan E., Lifshitz N., Bishop J., Evans A.C., Henkelman R.M., and Chen X.J. A three-dimensional MRI atlas of the mouse brain with estimates of the average and variability. Cereb. Cortex 15 (2005) 639-645
44. Lawrie S.M., and Abukmeil S.S. Brain abnormality in schizophrenia-a systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry 172 (1998) 110-120
45. Lewis D.A., and Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med. 12 (2006) 1016-1022
46. Lipina T., Labrie L., Weiner I., and Roder J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl.) 179 (2005) 54-67
47. Maeda K., Nwulia E., Chang J., Balkissoon R., Ishizuka K., Chen H., Zandi P., McInnis M.G., and Sawa A. Differential expression of Disrupted-in-Schizophrenia (DISC1) in bipolar disorder. Biol. Psychiatry 60 (2006) 929-935
48. Marchmont R.J., and Houslay M.D. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem. J. 187 (1980) 381-392
49. McIntosh A.M., Baig B.J., Hall J., Job D., Whalley H.C., Lymer G.K., Moorhead T.W., Owens D.G., Miller P., Porteous D., et al. Relationship of catechol-O-methyltransferase variants to brain structure and function in a population at high risk of psychosis. Biol. Psychiatry (2007) 10.1016/j.biolpsych.2006.05.020 in press. Published online September 30, 2006
50. Meyer-Lindenberg A., and Weinberger D.R. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci. 7 (2006) 818-827
51. Michaud E.J., Culiat C.T., Klebig M.L., Barker P.E., Cain K.T., Carpenter D.J., Easter L.L., Foster C.M., Gardner A.W., Guo Z.Y., et al. Efficient gene-driven germ-line point mutagenesis of C57BL/6J mice. BMC Genomics 6 (2005) 164
52. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A.M., Devon R.S., St Clair D.M., Muir W.J., Blackwood D.H.R., and Porteous D.J. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9 (2000) 1415-1423
53. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (2005) 1187-1191
54. Miyoshi K., Honda A., Baba K., Taniguchi M., Oono K., Fujita T., Kuroda S., Katayama T., and Tohyama M. Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatry 8 (2003) 685-694
55. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., and Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 3 (2004) 287-302
56. Niethammer M., Smith D.S., Ayala R., Peng J., Ko J., Lee M.S., Morabito M., and Tsai L.H. NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron 28 (2000) 697-711
57. O'Donnell J.M., and Zhang H.T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 25 (2004) 158-163
58. Okabe T., Nakamura T., Nishimura Y.N., Kohu K., Ohwada S., Morishita Y., and Akiyama T. RICS, a novel GTPase-activating protein for Cdc42 and Rac1, is involved in the beta-catenin-N-cadherin and N-methyl-D-aspartate receptor signaling. J. Biol. Chem. 278 (2003) 9920-9927
59. Ozeki Y., Tomoda T., Kleiderlein J., Kamiya A., Bord L., Fujii K., Okawa M., Yamada N., Hatten M.E., Snyder S.H., et al. Disrupted-in-Schizophrenia-1 (DISC1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc. Natl. Acad. Sci. USA 100 (2003) 289-294
60. Paylor R., and Crawley J.N. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl.) 132 (1997) 169-180
61. Perry W., and Braff D.L. Information-processing deficits and thought disorder in schizophrenia. Am. J. Psychiatry 151 (1994) 363-367
62. Porteous D.J., Thomson P., Brandon N.J., and Millar J.K. The genetics and biology of Disc1-an emerging role in psychosis and cognition. Biol. Psychiatry 60 (2006) 123-131
63. Pothion S., Bizot J.C., Trovero F., and Belzung C. Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav. Brain Res. 155 (2004) 135-146
64. Pouzet B., Anderson M.P., and Hogg S. Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. Psychopharmacology (Berl.) 178 (2005) 9-16
65. Ralph R.J., Paulus M.P., and Geyer M.A. Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J. Pharmacol. Exp. Ther. 298 (2001) 148-155
66. Rascle C., Mazas O., Vaiva G., Tournant M., Raybois O., Goudemand M., and Thomas P. Clinical features of latent inhibition in schizophrenia. Schizophr. Res. 51 (2001) 149-161
67. Rogers R.J., and Cole J.C. Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur. J. Pharmacol. 261 (1994) 321-325
68. Ross C.A., Margolis R.L., Reading S.A.J., Pletnikov M., and Coyle J.T. Neurobiology of schizophrenia. Neuron 52 (2006) 139-153
69. Sakic B., Denburg J.A., Denburg S.D., and Szechtman H. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve-shift study. Brain Res. Bull. 41 (1996) 305-311
70. Sakuraba Y., Sezutsu H., Takahasi K.R., Tsuchihashi K., Ichikawa R., Fujimoto N., Kaneko S., Nakai Y., Uchiyama M., Goda N., et al. Molecular characterization of ENU mouse mutagenesis and archives. Biochem. Biophys. Res. Commun. 336 (2005) 609-616
71. Sankoorikal G.M.V., Kaercher K.A., Boon C.J., Lee J.K., and Brodkin E.S. A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biol. Psychiatry 59 (2006) 415-423
72. Scheider H.H. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem. Pharmacol. 33 (1984) 1690-1693
73. Schurov I.L., Handford E.J., Brandon N.J., and Whiting P.J. Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol. Psychiatry 9 (2004) 1100-1110
74. Shinoda T., Taya S., Tsuboi D., Hikita T., Matsuzawa R., Kuroda S., Iwamatsu A., and Kaibuchi K. DISC1 regulates neurotrophin-induced axon elongation via interaction with Grb2. J. Neurosci. 27 (2007) 4-14
75. Stowers L., Holy T.E., Meister M., Dulac C., and Koentges G. Loss of sex discrimination and male-male aggression in mice deficient for TRP2. Science 295 (2002) 1493-1500
76. Strakowski S.M., DelBello M.P., Sax K.W., Zimmerman M.E., Shear P.K., Hawkins J.M., and Larson E.R. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch. Gen. Psychiatry 56 (1999) 254-260
77. Swerdlow N.R., Braff D.L., Taaid N., and Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 51 (1994) 139-154
78. Till B.J., Burtner C., Comai L., and Henikoff S. Mismatch cleavage by single-strand specific nucleases. Nucleic Acids Res. 32 (2004) 2632-2641
79. Ueda T., Greengard P., Berzins K., Cohen R.S., Blomberg F., Grab D.J., and Siekevitz P. Subcellular distribution in cerebral cortex of two proteins phosphorylated by a cAMP-dependent protein kinase. J. Cell Biol. 83 (1979) 308-319
80. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22 (1983) 267-272
81. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl.) 169 (2003) 257-297
82. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., and Rawlins J.N. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment. Br. J. Psychiatry 172 (1998) 243-249
83. Willner P. Validity, reliability and utility of the chronic stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl.) 134 (1997) 319-329
84. Wright I.C., Rabe-Hesketh S., Woodruff P.W.R., David A.S., Murray R.M., and Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 157 (2000) 16-25
85. Zhang H.T., Huang Y., Jin S.L.C., Frith S.A., Suvarna N., Conti M., and O'Donnell J.M. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27 (2002) 587-595
86. Zheng Q.Y., Johnson K.R., and Erway L.C. Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Hear. Res. 130 (1999) 94-107